149 related articles for article (PubMed ID: 27295141)
1. Addition of Everolimus Post VEGFR Inhibition Treatment Failure in Advanced Sarcoma Patients Who Previously Benefited from VEGFR Inhibition: A Case Series.
ElNaggar AC; Hays JL; Chen JL
PLoS One; 2016; 11(6):e0156985. PubMed ID: 27295141
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study.
García Del Muro X; Maurel J; Martínez Trufero J; Lavernia J; López Pousa A; de Las Peñas R; Cubedo R; Berros JP; Casado Herráez A; de Juan A; Martín Broto J
Invest New Drugs; 2018 Jun; 36(3):468-475. PubMed ID: 29527631
[TBL] [Abstract][Full Text] [Related]
3. Imatinib and everolimus in patients with progressing advanced chordoma: A phase 2 clinical study.
Stacchiotti S; Morosi C; Lo Vullo S; Casale A; Palassini E; Frezza AM; Dinoi G; Messina A; Gronchi A; Cavalleri A; Venturelli E; Morelli D; Pilotti S; Collini P; Brich S; Tamborini E; Mariani L; Casali PG
Cancer; 2018 Oct; 124(20):4056-4063. PubMed ID: 30216418
[TBL] [Abstract][Full Text] [Related]
4. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors.
Zhu M; Molina JR; Dy GK; Croghan GA; Qi Y; Glockner J; Hanson LJ; Roos MM; Tan AD; Adjei AA
Invest New Drugs; 2020 Dec; 38(6):1755-1762. PubMed ID: 32328844
[TBL] [Abstract][Full Text] [Related]
6. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.
Karavasilis V; Seddon BM; Ashley S; Al-Muderis O; Fisher C; Judson I
Cancer; 2008 Apr; 112(7):1585-91. PubMed ID: 18278813
[TBL] [Abstract][Full Text] [Related]
7. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N
Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558
[TBL] [Abstract][Full Text] [Related]
8. A role for maintenance therapy in managing sarcoma.
Ray-Coquard I; Le Cesne A
Cancer Treat Rev; 2012 Aug; 38(5):368-78. PubMed ID: 21843915
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series.
Bupathi M; Hays JL; Chen JL
PLoS One; 2017; 12(11):e0188116. PubMed ID: 29141017
[TBL] [Abstract][Full Text] [Related]
10. Oral trofosfamide: an active and well-tolerated maintenance therapy for adult patients with advanced bone and soft tissue sarcomas. Results of a retrospective analysis.
Reichardt P; Pink D; Tilgner J; Kretzschmar A; Thuss-Patience PC; Dörken B
Onkologie; 2002 Dec; 25(6):541-6. PubMed ID: 12566899
[TBL] [Abstract][Full Text] [Related]
11. Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas.
Mita MM; Gong J; Chawla SP
Expert Rev Clin Pharmacol; 2013 Sep; 6(5):465-82. PubMed ID: 23971829
[TBL] [Abstract][Full Text] [Related]
12. Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
Yoo C; Lee J; Rha SY; Park KH; Kim TM; Kim YJ; Lee HJ; Lee KH; Ahn JH
Invest New Drugs; 2013 Dec; 31(6):1602-8. PubMed ID: 24037083
[TBL] [Abstract][Full Text] [Related]
13. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.
Calvo E; Escudier B; Motzer RJ; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Ravaud A; Kim D; Panneerselvam A; Anak O; Figlin RA
Eur J Cancer; 2012 Feb; 48(3):333-9. PubMed ID: 22209391
[TBL] [Abstract][Full Text] [Related]
14. Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy.
Zucali PA; De Pas T; Palmieri G; Favaretto A; Chella A; Tiseo M; Caruso M; Simonelli M; Perrino M; De Vincenzo F; Toffalorio F; Damiano V; Pasello G; Garbella E; Ali M; Conforti F; Ottaviano M; Cioffi A; De Placido S; Giordano L; Bertossi M; Destro A; Di Tommaso L; Santoro A
J Clin Oncol; 2018 Feb; 36(4):342-349. PubMed ID: 29240542
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study.
Thiery-Vuillemin A; Theodore C; Jacobasch L; Schmitz J; Papandreou C; Guillot A; Emmanouilides C; Slimane K; Kelkouli N; Kim S; Nguyen Tan Hon T
Clin Genitourin Cancer; 2015 Jun; 13(3):231-8. PubMed ID: 25456838
[TBL] [Abstract][Full Text] [Related]
16. [Responses of 109 adult soft tissue sarcoma patients to chemotherapy].
Qiu MZ; Xu F; Wang SS; Luo HY; Wang F; Li FH; Sun XF; Xu GC; Lin TY; Huang HQ; Jiang WQ; Guan ZZ; Xu RH
Ai Zheng; 2007 Dec; 26(12):1344-9. PubMed ID: 18076798
[TBL] [Abstract][Full Text] [Related]
17. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
Grünwald V; Karakiewicz PI; Bavbek SE; Miller K; Machiels JP; Lee SH; Larkin J; Bono P; Rha SY; Castellano D; Blank CU; Knox JJ; Hawkins R; Anak O; Rosamilia M; Booth J; Pirotta N; Bodrogi I;
Eur J Cancer; 2012 Feb; 48(3):324-32. PubMed ID: 21803569
[TBL] [Abstract][Full Text] [Related]
18. The role of mTOR inhibitors for treatment of sarcomas.
Mita MM; Tolcher AW
Curr Oncol Rep; 2007 Jul; 9(4):316-22. PubMed ID: 17588357
[TBL] [Abstract][Full Text] [Related]
19. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.
Busch J; Seidel C; Erber B; Issever AS; Hinz S; Kempkensteffen C; Magheli A; Miller K; Grünwald V; Weikert S
Eur Urol; 2013 Jul; 64(1):62-70. PubMed ID: 22999519
[TBL] [Abstract][Full Text] [Related]
20. First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study.
Demetri GD; Le Cesne A; Chawla SP; Brodowicz T; Maki RG; Bach BA; Smethurst DP; Bray S; Hei YJ; Blay JY
Eur J Cancer; 2012 Mar; 48(4):547-63. PubMed ID: 22240283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]